Creating Hope Reauthorization Act
United States116th CongressHR-4439House of Representatives
Updated: Sep 30, 2020
Summary
Creating Hope Reauthorization Act This bill reauthorizes a Food and Drug Administration (FDA) program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.) Specifically, the bill reauthorizes the program through FY2024, but the FDA may award a voucher afterwards in certain instances.
Bill texts
Timeline
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5023)
House of Representatives
Motion to reconsider laid on the table Agreed to without objection.
House of Representatives
The title of the measure was amended. Agreed to without objection.
House of Representatives
Received in the Senate.
Senate